Epilepsy
Conditions
Interventions
Trial group:For BRV treatment, the initial doses for patients weighing 50 kg are 1.5–3 mg/kg/day, 1–2.5 mg/kg/day, 1–2 mg/kg/day, and 50–100 mg/day, respectively. Doses should be adjusted based on cli
Sponsors
Capital Children's Medical Center, Capital Medical University (Formerly known as the Capital Institute of Pediatrics)
Eligibility
Sex/Gender
All
Age
4 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects aged >4 years, regardless of gender; 2. Children meet the 2017 International League Against Epilepsy (ILAE) diagnostic criteria for epilepsy based on clinical history and/or electroencephalogram; 3. Evaluated by at least two physicians and one pharmacist as requiring addition of BRV; 4. Seizure frequency >2 times per month, with inter-seizure intervals >24 hours; 5. Signed informed consent and voluntarily participating in the study.
Exclusion criteria
Exclusion criteria: 1.Patients taking antipsychotic drugs such as chlorpromazine, haloperidol, olanzapine, and risperidone, or those with mental illnesses such as schizophrenia, bipolar disorder, and depressive disorder; 2.Patients allergic to brivaracetam or pyrrolidone derivatives; 3.Patients currently being treated with levetiracetam; 4.Patients with symptomatic epilepsy caused by infectious, immune, or metabolic etiologies who are undergoing etiological treatment; 5.Patients with progressive neurological diseases, including degenerative central nervous system diseases and central nervous system tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 50% Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Seizure-Free Rate;Retention Rate;Adverse Event Incidence Rate;Quality of Life;Cognitive Function Score; | — |
Countries
China
Contacts
Public ContactJi Xinna
Capital Children's Medical Center, Capital Medical University (Formerly known as the Capital Institute of Pediatrics)
Outcome results
None listed